|
|
Blood, 1 December 2005, Vol. 106, No. 12, pp. 3917-3925.
Prepublished online as a Blood First Edition Paper on August 16, 2005; DOI 10.1182/blood-2005-04-1424.
Previous Article | Next Article 
Submitted April 7, 2005
Accepted July 25, 2005
NF- B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDS)
Daniella M Kerbauy, Vladimir Lesnikov, Nissa Abbasi, Sudeshna Seal, Bart Scott, and H J Deeg*
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington School of Medicine, Seattle, WA, USA
* Corresponding author; email: jdeeg{at}fhcrc.org; blarson@fhcrc.org.
Tumor necrosis factor (TNF)- , a potent stimulus of NF- B, is upregulated in myelodysplasia (MDS). Here, we show that bone marrow mononuclear cells (BMMC) and purified CD34+ cells from patients with low grade/early stage MDS (RA/RARS) have low levels of NF- B activity in nuclear extracts comparable to normal marrow, while patients with RA with excess blasts (RAEB) show significantly increased levels of activity (P=0.008). Exogenous TNF- enhanced NF- B nuclear translocation in MDS BMMC above baseline levels. Treatment with arsenic trioxide (ATO; 2-200 µM) inhibited NF- B activity in normal marrow, primary MDS, and ML1 cells, even in the presence of exogenous TNF- (20 ng/mL), and downregulated NF- B-dependent anti-apoptotic proteins, Bcl-XL, Bcl-2, XIAP, and FLIP, leading to apoptosis. However, overexpression of FLIP resulted in increased NF- B activity and rendered ML1 cells resistant to ATO-induced apoptosis. These data are consistent with the observed upregulation of FLIP and resistance to apoptosis with advanced MDS where ATO as a single agent may show only limited efficacy. However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF- B, may have considerable therapeutic activity.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. J. Mhyre, A. M. Marcondes, E. Y. Spaulding, and H. J. Deeg
Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
Blood,
January 15, 2009;
113(3):
649 - 658.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Dolniak, E. Katsoulidis, N. Carayol, J. K. Altman, A. J. Redig, M. S. Tallman, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, and L. C. Platanias
Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2
J. Biol. Chem.,
May 2, 2008;
283(18):
12034 - 12042.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Marcondes, A. J. Mhyre, D. L. Stirewalt, S.-H. Kim, C. A. Dinarello, and H. J. Deeg
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
PNAS,
February 26, 2008;
105(8):
2865 - 2870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C. Bornhauser, L. Bonapace, D. Lindholm, R. Martinez, G. Cario, M. Schrappe, F. K. Niggli, B. W. Schafer, and J.-P. Bourquin
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
Blood,
September 15, 2007;
110(6):
2084 - 2091.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio
Nuclear factor {kappa}B as a target for new drug development in myeloid malignancies
Haematologica,
September 1, 2007;
92(9):
1224 - 1229.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kannan-Thulasiraman, E. Katsoulidis, M. S. Tallman, J. S. C. Arthur, and L. C. Platanias
Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide
J. Biol. Chem.,
August 11, 2006;
281(32):
22446 - 22452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-C. Lee, I-C. Ho, W.-J. Lu, and J.-d. Huang
Enhanced Expression of Multidrug resistance-associated Protein 2 and Reduced Expression of Aquaglyceroporin 3 in an Arsenic-resistant Human Cell Line
J. Biol. Chem.,
July 7, 2006;
281(27):
18401 - 18407.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|